NCT04497805招募中2 期
A Phase 2 Clinical Study to Evaluate The Efficacy and Safety of ALLO-ASC-SHEET in the Subjects With Diabetic Wagner Grade II Foot Ulcers
Anterogen Co., Ltd.2 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2020年9月8日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 64
- 试验地点
- 2
- 主要终点
- Proportions of subjects who achieved complete wound closure.
研究概览
简要总结
This is a phase 2 double-blind clinical study to evaluate the efficacy and Safety of ALLO-ASC-SHEET in subjects with Diabetic Wagner Grade II Foot Ulcers, compared to placebo therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female between 18 and 80 years of age.
- •Diagnosed with Type I or Type II diabetes and has Wagner Grade II diabetic foot ulcers for longer than 4 weeks at the time of screening.
- •Foot ulcer located in the plantar or dorsal, with ulcer size between1.5 cm2 and 15 cm
- •Ulcer, Graded II by Wagner grade, and extended to muscle periosteum, muscle, tendon, or joint capsule, but not to bone.
- •Ulcer is free of necrotic debris,exhibits no signs of clinical infection.
- •Ulcer area blood circulation meets 1 of the following criteria:
- •A. Blood vessels around the ulcer detected by Doppler Test to have biphasic or triphasic flow B. Range of Ankle Brachial Index(ABI) is>0.7 to <1.3 C. Transcutaneous oxygen pressure (TcPO2) >30 mmHg.
- •Is able to give written informed consent prior to study start and to comply with the study requirements.
排除标准
- •Ulcer is of non-diabetic pathophysiology.
- •The ulcer has increased or decreased in size by ≥30% during 2 weeks screening period.
- •Patient is currently on higher dose antibiotic therapy as defined by increased dose or change in therapy from the initial treatment regimen at screening to treat index wound infection or patient is on suppressive antibiotic therapy for diabetic foot wound infection.
- •The longest dimension of the index wound exceeds 15 cm at the baseline visit.
- •Patient with skin lesion confirmed by biopsy (when Investigator deems suspicious) and then judged by Investigator to be an etiology other than diabetic foot ulcer (i.e.,example skin cancer in situ, pyoderma).
- •Current evidence of active charcot, osteomyelitis, cellulitis, or evidence of other infection including fever or purulentdrainage from wound site.
- •Is Human Immunodeficiency Virus (HIV) positive
- •Havesevere hepatic deficiencies.
- •Have a glycated hemoglobin A1c (HbA1c) level of >10%.
- •Have an allergic or hypersensitive reaction to bovine-derived proteins or fibrin glue.
- •Have severe renal function insufficiency documented with creatinine greater than 3.0 mg/dL.
- •Pregnant or breast-feeding.
- •Is unwilling to use an "effective" method of contraception during the study.
- •Have evidence of current infection including purulent drainage from the wound site.
- •Have a clinically relevant history of alcohol or drugs abuse.
- •Have postprandialblood sugar >350 mg/dL at screening.
- •Is not able to comply with the study requirements.
- •Is considered by the Investigator to have a significant disease which might impact the study.
- •Is considered not suitable for the study by Investigator.
- •Have a history of malignancy within the last 5 years (except basal cell carcinoma in situ).
- •Is currently or were enrolled in another clinical study within 60 days of screening.
- •Have undergone wound treatments with growth factors, dermal substitutes, or other biological therapies within the last 30 days.
- •Is receiving oral or parenteral corticosteroids (In doses greater than 10 mg per day), any immunosuppressive, or cytotoxic agents with unstable dose prior to 4 weeks from screening.
- •Cannot maintain off-loading process.
- •Panel reactive antibody (PRA) levels ≥ 20% at screening.
- •Venereal Disease Research Laboratory test (VDRL) or RPR positive
结局指标
主要结局
Proportions of subjects who achieved complete wound closure.
时间窗: During 12 weeks
Proportions of subjects who achieved complete wound closure during the 12 weeks.
次要结局
- Time to initial complete wound closure between the 2 groups.(During 12 weeks)
- Proportions of subjects who achieved complete wound closure between the 2 groups by the classification of wound size.(During 12 weeks)
- Proportions of subjects who achieved complete wound closure between the 2 groups by the classification of location of diabetic foot ulcer.(During 12 weeks)
- Durability of complete wound closure for the additional 24 weeks.(During 36 weeks)
- Changes in wound size compared to baseline between the 2 groups.(During 12 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Clinical Study of ALLO-ASC-SHEET in Subjects with Diabetic Foot UlcersDiabetic Foot UlcerNCT03754465Anterogen Co., Ltd.66
已完成
2 期
Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot UlcersDiabetic Foot UlcerNCT02619877Anterogen Co., Ltd.59
已完成
1 期
Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis BullosaDystrophic Epidermolysis BullosaNCT02579369Anterogen Co., Ltd.2
已完成
2 期
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled AsthmaAsthmaNCT05251259AstraZeneca670
终止
2 期
Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/IrinotecanGlioblastoma MultiformeNCT02060955CytoVac A/S25